Source - SMW
AstraZeneca and MedImmune, its global biologics research and development arm, have announced that the US Food and Drug Administration has accepted a supplemental biologics licence application   for Imfinzi (durvalumab) for the treatment of patients with locally advanced (stage III) unresectable non-small cell lung cancer   whose disease has not progressed following platinum-based chemoradiation therapy. 

The FDA has granted Imfinzi priority review status.

AstraZeneca said the US FDA sBLA submission acceptance was an important milestone for Imfinzi in a disease state where patients need better treatment options and outcomes. 

It said that currently, the standard of care for patients with this earlier stage of lung disease is active monitoring following concurrent chemoradiation.

At 8:28am: (LON:AZN) AstraZeneca PLC share price was -6.5p at 5148.5p